BIVI - מכפיל P/S עתידי BioVie

BioVie Inc. (BIVI) management is focusing on dementia and liver pathology therapies, foregoing dividend payments to fund clinical trial development. The GURU.Markets terminal displays a forward P/S ratio chart, where the current reading is , confirming market confidence. The production of hepatoprotectors has been outsourced to external CDMO partners to optimize processes, while innovative drugs target inflammation and brain insulin resistance.

Forward P/S assesses market capitalization relative to expected annual sales, allowing an investor to determine the extent of overpayment for future cash flows via the projected P/S parameter. For BioVie Inc. (BIVI), this metric reflects the speculative value of potential drug approvals rather than a market cycle, where the coefficient's dynamics depend directly on the success of clinical trials and the availability of venture capital.